Stocks · News reference
Silexion Therapeutics shares are trading lower. The company announced initiation of its Phase 2/3 clinical trial of SIL204, lead siRNA product candidate, at TASMC.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 2:10 PM
- Checked
- Jul 29, 2026, 2:09 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Silexion Therapeutics Q2 EPS $(5.17) Misses $(2.12) Estimate
Silexion Therapeutics (NASDAQ:SLXN) reported quarterly losses of $(5.17) per share which missed the analyst consensus estimate of $(2.12) by 143.87 percent. This is a 88.03 percent increase over losses of $(43.20) per
Read original at benzingaNasdaq Surges 150 Points; US Inflation Rate Slows To 3.4% In July
US stocks rise, Nasdaq up 150 points. Dow up 0.13%, Nasdaq up 0.62%, S&P 500 up 0.35%. IT shares up 1.2%, healthcare down 0.9%. CPI rises 3.4%.
Read original at benzingaSilexion Therapeutics shares are trading lower after the company announced the pricing of its $2.5 million public offering of 3,846,161 shares at $0.65 per share.
Read original at benzinga